Comparative Pharmacology
Head-to-head clinical analysis: UTICILLIN VK versus VEETIDS 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UTICILLIN VK versus VEETIDS 500.
UTICILLIN VK vs VEETIDS '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Uticillin VK (penicillin V potassium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) in the bacterial cytoplasmic membrane, thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
VEETIDS '500' (cefuroxime axetil) is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking transpeptidation and leading to cell lysis. It has activity against both gram-positive and gram-negative bacteria.
250-500 mg orally every 6-8 hours for 10 days for streptococcal pharyngitis; 250-500 mg orally every 6 hours for pneumococcal infections.
1 tablet (500 mg) orally twice daily for 7 days.
None Documented
None Documented
0.5-1.0 hour (prolonged in renal impairment; e.g., up to 10 hours in anuria)
4-6 hours (prolonged in renal impairment; requires dose adjustment if CrCl <30 mL/min)
Renal: 70-80% unchanged via tubular secretion and glomerular filtration; biliary/fecal: minor (about 10%)
Renal: 60-80% unchanged; biliary/fecal: 15-25% as metabolites
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic